Scientific Innovation is the foundation for all our products and services.

For us EYE-INSPIRED INNOVATION is all about collaborating with the brightest around the world, gaining insights from patients and clinicians, and translating those insights into improvements in products, patient care, and ultimately life itself.

Leonardo da Vinci first illustrated the concept of contact lenses in 1508. In his “Codex of the Eye” he described a method of directly altering corneal power. More than 500 years later, Johnson & Johnson Vision embraces this spirit of invention. We introduced the world’s first disposable soft contact lens under the brand name ACUVUE^® in 1987 and we continue to be fervently focused on bringing advances to what we consider to be one of the most fascinating wearable technologies of our time — contact lenses.

Refractive surgeries are thought to have been carried out in ancient Greece. Today, laser technologies have revolutionized vision corrective surgery by providing a degree of safety and precision that was previously unattainable.

Cataract surgery, one of the oldest surgical procedures on record, was first documented in the fifth century BC! Today it’s one of the most common surgeries in the U. S. In 2017 Johnson & Johnson acquired Abbott Medical Optics and is a global leader in ophthalmic surgery, including refractive and cataract surgery and intraocular lens (IOL) implants.

Early in the fifth century, oat herbs were placed on the eye to treat Dry Eye Disease (DED).  Later in the 11th century, topically applied grape wine ashes, vinegar and honey were used. Fortunately, with the help of science, we’ve come a long way since then but there are still more than 340 million people globally who suffer from DED. We also now understand that Meibomian Gland Dysfunction (MGD) is a leading cause of DED, affecting 86% of dry eye patients. As a leader in medical device technologies, Johnson & Johnson Vision is focused on delivering scientific innovation designed specifically for treating MGD and DED.

To help create this reality, we are making significant investments in new science and technologies as well as insights and analytics. 

Our research agenda addresses a broad spectrum of eye disease - from myopia that often strikes children at a young age through to advanced macular disease. And we have in late-stage development brand new categories of contact lenses that have the potential to deliver benefits beyond vision correction.